Targeted inhibition of mTOR by BML-275 induces mitochondrial-mediated apoptosis and autophagy in prostate cancer

Prostate Cancer (PCa) is the most frequently diagnosed Cancer among men and the second leading cause of death in Western countries. Clinically, screening drugs and develop developing new therapeutics to treat PCa is of great significance. In this study, BML-275 was demonstrated to exert potent antitumor effects in PCa by antagonizing mTOR activity. In cultured PCa cells, BML-275 treatment reduced the expression levels of c-Myc and Survivin, promoted the activation of p53, and thereby induced p21/cyclin D1/CDK4/6-dependent cell cycle G1/S arrest. As a result, BML-275 inhibited cellular proliferation and induced mitochondrial-mediated Apoptosis. In addition, BML-275 treatment triggered Autophagy. Interestingly, EACC-mediated suppression of Autophagy did not affect BML-275-induced proliferation and Apoptosis. Nude mouse tumorigenic experiments also confirmed that BML-275 inhibited PCa growth, induced PCa cell Apoptosis and Autophagy. Mechanistically, the activities of PI3K/Akt and AMPK pathways were downregulated by BML-275 treatment in vitro and in vivo. Importantly, mTOR, a common downstream negative protein of PI3K/Akt and AMPK signaling, was induced to inactivate, which may be associated with the induction of Apoptosis and Autophagy. The pharmacological activation of mTOR by MHY1485 abolished the induction of Apoptosis and Autophagy of BML-275. Molecular docking results showed that BML-275 can bind to the FKRP12-rapamycin binding site on mTOR protein, and thereby may have the same inhibitory activity on mTOR as rapamycin. Thus, these findings indicated that BML-275 induces mitochondrial-mediated Apoptosis and Autophagy in PCa by targeting mTOR inhibition. BML-275 may be a potential candidate for the treatment of PCa.

AMPK; BML-275; PI3K/AKT; Prostate cancer (PCa); mTOR.